Peter Forsyth MD

Oncology•Tampa, FL

Neuro-Oncology

Chairman of the Neuro-Oncology Program at Moffitt Cancer Center and Professor of Oncology at the University of South Florida

Request Appointment

12902 USF Magnolia DriveTampa, FL 33612
Book by Phone+1(484) 929-2876
Fax+1 813-449-8246

Education & Training

Mayo Clinic College of Medicine and Science (Rochester)Residency, Neurology, 1988 - 1991
Michael G. DeGroote School of MedicineClass of 1987

Certifications & Licensure

FL State Medical License 2011 - 2027
CT State Medical License 1993 - 1994
American Board of Psychiatry and Neurology Neurology

Clinical Trials

RO4929097 in Treating Patients With Recurrent Invasive Gliomas Start of enrollment: 2011 Jul 01
Terminated
Phase 1
A Trial Looking at Rituximab and Chemotherapy as a Treatment for Follicular Lymphoma in Elderly Patients
COMPLETED
PHASE3
Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma Start of enrollment: 2011 Sep 01
Completed
Phase 2
Nuvigil or Placebo in Newly Diagnosed Malignant Glioma Start of enrollment: 2010 Dec 01
Terminated
Phase 2
A Phase II Study of Oral LDE225 in Patients With Hedge-Hog (Hh)-Pathway Activated Relapsed Medulloblastoma (MB) Start of enrollment: 2013 May 06
Completed
Phase 2
Fractionated Stereotactic Radiotherapy (FSRT) in Treatment of Brain Metastases Start of enrollment: 2014 Oct 09
Terminated
Phase 1
Avelumab With Radiotherapy in Patients With Leptomeningeal Disease Start of enrollment: 2019 Jun 10
COMPLETED
PHASE1
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma Start of enrollment: 2019 Jul 30
RECRUITING
PHASE2, PHASE3
Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease Start of enrollment: 2020 Dec 10
RECRUITING
PHASE1, PHASE2
Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases Start of enrollment: 2021 Nov 30
RECRUITING
PHASE1, PHASE2
Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases Start of enrollment: 2023 Jun 06
COMPLETED
EARLY_PHASE1
Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer Start of enrollment: 2016 May 01
ACTIVE_NOT_RECRUITING
PHASE2
A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV) Start of enrollment: 2023 Aug 22
RECRUITING
PHASE1
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer Start of enrollment: 2022 Dec 19
RECRUITING
PHASE2
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Comparative Analysis of Intracranial Response Assessment Criteria in Patients With Melanoma Brain Metastases Treated With Combination Nivolumab + Ipilimumab in CheckMa...
Raymond Y Huang, Gilbert Youssef, Thomas Nelson, Patrick Y Wen, Peter Forsyth
Journal of Clinical Oncology. 2025-04-01
Phase II Trial of Pembrolizumab in Combination With Bevacizumab for Untreated Melanoma Brain Metastases.
Sarah A Weiss, Dijana Djureinovic, Wei Wei, Thuy Tran, Matthew Austin
Journal of Clinical Oncology. 2025-03-06
1 citations
NANO-LM: An updated scorecard for the clinical assessment of patients with leptomeningeal metastases.
Emilie Le Rhun, Lakshmi Nayak, Mary Jane Lim-Fat, Roberta Rudà, Elena Pentsova
Neuro-Oncology. 2025-02-10

Press Mentions

Molecular Characteristics of Leptomeningeal Melanoma MetastasesJanuary 10th, 2020
Molecular Characteristics of Leptomeningeal Melanoma MetastasesJanuary 10th, 2020
Shop TalkOctober 20th, 2019
Join now to see all